TPM3 and colorectal carcinoma: Entrectinib (RDX-101, NMS-P626), a multikinase inhibitor, was shown to suppress TPM3-TRKA protein phosphorylation in mice with CRC harbouring a TPM3-NTRK1 gene fusion [43], and further showed efficacy in three clinical trials including patients with NTRK gene fusions [114, 115].